氯己定与聚维酮碘用于玻璃体腔注射消毒的系统综述与Meta分析
该系统综述与Meta分析比较氯己定(CHX)与聚维酮碘(PI)预防注射后眼内炎的疗效与安全性,共纳入7项研究。两者推测性、培养阳性及培养阴性眼内炎发生率均无显著差异,但CHX在安全性及疼痛方面表现更优,且眼内炎病例中表皮葡萄球菌培养阳性比值更低。
要点
- CHX与PI的推测性、培养阳性及培养阴性眼内炎发生率均无显著差异。
- 眼内炎病例中CHX组表皮葡萄球菌培养阳性比值显著低于PI组(OR=0.15)。
- CHX患者不耐受极少,疼痛减轻优于PI,PI角膜上皮病变多于CHX。
核心结论
- CHX与PI的推测性、培养阳性及培养阴性注射后眼内炎发生率无显著差异。
- 两种消毒剂相关眼内炎病例的末次观察最佳矫正视力预后相当。
- CHX的安全性和疼痛特征优于PI,且眼内炎病例中表皮葡萄球菌培养阳性比值更低。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase和Cochrane Library从2000年1月至2024年7月的文献。
- 纳入比较CHX与PI用于注射后眼内炎预防、功能结局或安全性结局的研究,共纳入7项研究。
- 采用随机效应Meta分析,二分类结局用Mantel-Haenszel法,连续结局用逆方差法。
主要发现
- 推测性注射后眼内炎发生率:CHX组60/185,849(0.032%)vs PI组69/269,491(0.026%),无显著差异。
- 培养阳性注射后眼内炎:CHX组30/185,849(0.016%)vs PI组24/269,491(0.009%),OR=2.03,95%CI=[0.74, 5.58],P=.17。
- 培养阴性注射后眼内炎:CHX组30/185,849(0.016%)vs PI组45/269,491(0.017%),OR=0.97,95%CI=[0.45, 2.06],P=.93。
- 三项研究共54只培养阳性眼内炎眼:表皮葡萄球菌培养阳性比值CHX组9/30(30.0%)vs PI组18/24(75.0%),OR=0.15,95%CI=[0.04, 0.54],P=.004;金黄色葡萄球菌(P=.64)、草绿色链球菌(P=.46)、轻型链球菌(P=.83)和粪肠球菌(P=.46)的比值无显著差异。
- 眼内炎病例末次观察最佳矫正视力在CHX与PI组间无显著差异(P=.67)。
关键数值与推荐
- 主要结局为CHX与PI的注射后眼内炎发生率比较。
- 次要结局包括最佳矫正视力、患者不耐受、疼痛、安全性终点及培养标本。
临床怎么用
- CHX与PI在预防注射后眼内炎方面疗效无显著差异。
- CHX患者不耐受极少,疼痛减轻优于PI,PI角膜上皮病变多于CHX。
- 两种消毒剂比较的眼表微生物分离减少无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: While povidone-iodine (PI) is a commonly used antiseptic solution for postinjection endophthalmitis (PIE) prophylaxis, chlorhexidine (CHX) may be better tolerated by patients. This systematic review and meta-analysis aims to comprehensively compare the efficacy and safety of CHX and PI for PIE prophylaxis. DESIGN: Systematic Review and Meta-Analysis. METHODS: MEDLINE, Embase, and the Cochrane Library were systematically searched for relevant literature from January 2000 to July 2024. Studies that compared CHX with PI for either PIE prophylaxis, functional outcomes, or safety outcomes were included. A random-effects meta-analysis was performed, using the Mantel-Haenszel method for dichotomous outcomes and inverse variance method for continuous outcomes. The primary outcomes were the comparative PIE incidence after CHX versus PI. Secondary outcomes pertained to best-corrected visual acuity (BCVA), patient intolerance, pain, safety endpoints, and specimens cultured. RESULTS: A total of seven studies were included. The incidence of presumed PIE (nCHX = 60/185,849, 0.032% vs nPI = 69/269,491, 0.026%), culture-positive PIE (nCHX = 30/185,849 0.016% vs nPI = 24/269,491, 0.009%; odds ratio [OR] = 2.03, 95% confidence interval [CI] = [0.74, 5.58], P = .17) and culture-negative PIE (nCHX = 30/185,849, 0.016% vs nPI = 45/269,491, 0.017%; OR = 0.97, 95% CI = [0.45, 2.06], P = .93) were nonsignificantly different between PI and CHX groups. No significant risk differences were observed for these outcomes. Across three studies reporting on 54 eyes with culture-positive endophthalmitis, the odds of having positive Staphylococcus epidermidis cultures were significantly lower in the CHX group (nCHX = 9/30, 30.0% vs nPI = 18/24, 75.0%; OR = 0.15, 95% CI = [0.04, 0.54], P = .004); however, the odds were nonsignificantly different for Staphylococcus aureus (P = .64), Streptococcus viridans (P = .46), Streptococcus mitis (P = .83), and Enterococcus faecalis (P = .46). In cases of endophthalmitis, the mean BCVA was nonsignificantly different between CHX and PI groups at the last study observation (P = .67). The systematic review revealed minimal patient intolerance to CHX, more favorable reductions in pain with CHX than PI, greater corneal epitheliopathy with PI than CHX, and nonsignificantly different reductions in ocular surface microbial isolates between comparators. CONCLUSIONS: CHX and PI were associated with nonsignificantly different rates of presumed, culture-positive, and culture-negative PIE. Endophthalmitis cases associated with both antiseptic agents had a comparable prognosis with respect to BCVA. However, CHX exhibited a more favorable safety and pain profile compared to PI and was associated with a lower odds of positive S. epidermidis cultures in endophthalmitis cases.
引用
- Mihalache A, Tao BK, Huang RS, et al. Chlorhexidine Versus Povidone-Iodine for Intravitreal Injection Antisepsis: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2025. PMID: 40154909. doi:10.1016/j.ajo.2025.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。